Progress of phosphatidylinositol 3-kinase signaling pathway and its inhibitors in lymphoma
10.3760/cma.j.issn.1009-9921.2019.09.016
- VernacularTitle: 磷脂酰肌醇3-激酶信号通路及其抑制剂在淋巴瘤中的研究进展
- Author:
Yahong XU
1
;
Chuntuan LI
;
Xiongpeng ZHU
Author Information
1. Department of Hematology, the First Hospital of Quanzhou, Fujian Medical University, Quanzhou 362000, China
- Publication Type:Review
- Keywords:
Lymphoma;
Phosphatidylinositol 3-kinase;
Signal transduction;
Protein kinase inhibitors
- From:
Journal of Leukemia & Lymphoma
2019;28(9):568-571
- CountryChina
- Language:Chinese
-
Abstract:
The over-activation of phosphatidylinositol 3-kinase (PI3K) signaling pathway is closely related to the occurrence and development of malignant tumors. The abnormal expression of this pathway is involved in the regulation of cell growth, malignant transformation, apoptosis and metastasis. The targeted therapy for specific sites of PI3K signaling pathway is a new research hotspot. A variety of different types of PI3K inhibitors have been marketed or entered clinical trials and have shown considerable efficacy in the treatment of malignant lymphomas. In this view, the recent advances in activation patterns of PI3K signaling pathway in lymphoma and PI3K inhibitors are summarized.
